MedTrace Logo

Safety of the HIV Vaccine 732462 in HIV Infected Subjects Aged 18 to 55 Years Old

NCT00814762 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2018-06-18

No results posted yet for this study

Summary

The purpose of this research study is to evaluate the safety of GSK Biologicals' investigational HIV vaccine 732462, administered as two doses approximately 1 month apart, in a small group of HIV infected people.

Conditions

  • AIDS

Interventions

BIOLOGICAL

HIV Vaccine 732462

Two doses reconstituted adjuvanted vaccine, injected intramuscularly, at an interval of approximately one month.

BIOLOGICAL

Placebo vaccine

Two doses of placebo, injected intramuscularly, at an interval of approximately one month

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-03
Primary Completion
2010-08-18
Completion
2010-08-18

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00814762 on ClinicalTrials.gov